Major determinants of survival in recurrent endometrial cancer-the role of secondary cytoreductive surgery: a multicenter study.
Int J Gynecol Cancer
; 33(10): 1572-1579, 2023 10 02.
Article
in En
| MEDLINE
| ID: mdl-37648408
ABSTRACT
OBJECTIVE:
The main objective of the study was to assess the influence of different clinical and therapeutic variables on the oncological outcomes of patients with endometrial cancer relapse. In particular, we evaluated the impact of cytoreductive surgery with the achievement of complete gross resection.METHODS:
This is a multicenter retrospective cohort study conducted in three centers in Italy and including all patients with first relapse of endometrial cancer from January 2010 to December 2021.RESULTS:
Data from 331 women with recurrent endometrial cancer were analyzed. Secondary cytoreductive surgery was performed in 56.2% of cases (186 patients). Complete gross resection was achieved in 178 patients (95.7%). Complete gross resection conferred a statistically significant survival benefit both for post-relapse survival and post-relapse free survival (3 years post-relapse survival 75.4% vs 56.4%, p<0.001; 3 years post-relapse free survival 32.6% vs 26.5%, p=0.027). At multivariate Cox regression analysis, age ≥75 years, Eastern Cooperative Oncology Group Performance Status ≥2, the advanced-metastatic risk group, complete gross resection, and multiple site relapses were identified as independent significant predictors for post-relapse survival; regarding post-relapse free survival, only age ≥75, the high and advanced-metastatic risk groups, and complete gross resection confirmed their statistical significance.CONCLUSIONS:
Secondary cytoreductive surgery with achievement of complete gross resection was confirmed to be an independent positive predictor for survival in patients with recurrent endometrial cancer and should be considered a valid primary treatment in the therapeutic decision-making process.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Endometrial Neoplasms
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
Language:
En
Journal:
Int J Gynecol Cancer
Journal subject:
GINECOLOGIA
/
NEOPLASIAS
Year:
2023
Type:
Article
Affiliation country:
Italy